Trevi Therapeutics | 8-K: Trevi Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates Reaffirming Clinical Trial Guidance
Trevi Therapeutics | 8-K: Current report
Trevi Therapeutics | 8-K: Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
Trevi Therapeutics | DEFA14A: Others
Trevi Therapeutics | DEF 14A: Definitive information statements
Trevi Therapeutics | 8-K: Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updates
Trevi Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Trevi Therapeutics | 8-K: Trevi Therapeutics Announces Third Quarter 2023 Financial Results and Provides Business Update
Trevi Therapeutics | S-3/A: Registration statement for specified transactions by certain issuers (Amendment)
Trevi Therapeutics | 8-K: Trevi Therapeutics Announces Second Quarter 2023 Financial Results and Provides Business Update
Trevi Therapeutics | S-3: Registration statement for specified transactions by certain issuers
Trevi Therapeutics | 8-K: Current report
Trevi Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Trevi Therapeutics | 8-K: Trevi Therapeutics Announces First Quarter 2023 Financial Results and Provides Business Update
Trevi Therapeutics | DEFA14A: Others
Trevi Therapeutics | DEF 14A: Definitive proxy statements
Trevi Therapeutics | PRE 14A: Preliminary proxy statement not related to a contested matter or merger/acquisition
Trevi Therapeutics | 8-K: Current report
Trevi Therapeutics | 8-K: Trevi Therapeutics Announces Fourth Quarter and Year End 2022 Financial Results and Provides Business Update
Trevi Therapeutics | 8-K: Trevi Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update
No Data